By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ZymoGenetics, Inc. 

1201 Eastlake Avenue East

Seattle  Washington  98102  U.S.A.
Phone: 206-442-6600 Fax: 206-442-6608

ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. The Company is developing a diverse pipeline of potential proprietary product candidates that are moving into and through clinical development. These span a wide array of clinical opportunities that include bleeding, autoimmune diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio.

Last Updated: 09-15-04

Key Statistics

Ownership: Public

Web Site: ZymoGenetics, Inc.
Employees: 475 (as of 12/31/2005)
Symbol: ZGEN

Company News
Blaze Bioscience Inc., Fred Hutchinson Cancer Research Center Spinoff with ZymoGenetics, Inc. (ZGEN) Vet at the Helm, Seeks to "Paint" Tumors 10/18/2011 8:12:47 AM
Bristol-Myers Squibb Company (BMY) to Keep a Seattle Presence; to Preserve About 275 ZymoGenetics, Inc. (ZGEN) Jobs 1/26/2011 6:48:15 AM
ZymoGenetics, Inc. (ZGEN) CEO Doug Williams Exits the Stage, Mulls Next Free Agent Move 11/8/2010 7:48:09 AM
Bristol-Myers Squibb Company (BMY) Third Quarter Featured Solid Operating Performance, Robust Clinical Data and the Strategic Acquisition of ZymoGenetics, Inc. (ZGEN) 10/26/2010 9:39:13 AM
Bristol-Myers Squibb Company (BMY) Completes Acquisition of ZymoGenetics, Inc. (ZGEN) 10/13/2010 10:07:42 AM
Bristol-Myers Squibb Company (BMY) Completes Tender Offer for ZymoGenetics, Inc. (ZGEN) with 94.9% of Shares Tendered 10/8/2010 9:49:27 AM
Novo Nordisk A/S (NVO) Completes Divestment of ZymoGenetics, Inc. (ZGEN) 10/8/2010 9:16:05 AM
ZymoGenetics, Inc. (ZGEN) and Bristol-Myers Squibb Company (BMY) to Present PEG-Interferon Lambda Phase 2a Interim Clinical Trial Results at AASLD 2010 10/4/2010 10:40:57 AM
ZymoGenetics, Inc. (ZGEN) Reports Favorable Survival Data from IL-21 Phase 2a Clinical Trial in Melanoma 9/29/2010 9:55:42 AM
ZymoGenetics, Inc. (ZGEN)'s Skin Cancer Drug Shows Promise in Study 9/29/2010 6:37:13 AM